Eylea 8 mg Study Finds Vision and Retinal Gains in Routine Care
Bayer presented 24-week SPECTRUM findings showing vision and retinal outcomes with Eylea 8 mg in routine care for neovascular age-related macular degeneration and diabetic macular edema.
This article was automatically drafted and passed editorial compliance checks. It synthesizes public source metadata and is not a substitute for individual care or clinical review.
Bayer presented the first 24-week analysis from SPECTRUM, a global prospective non-interventional real-world study involving more than 3,700 patients across 18 countries. The study included people with neovascular age-related macular degeneration or diabetic macular edema and divided them into four cohorts according to prior treatment experience.
The findings are limited to a 24-week analysis of patients with these two retinal conditions. Because SPECTRUM was non-interventional, its observations reflect routine-care outcomes and do not by themselves establish comparative efficacy against another treatment or regimen.
Outcomes differed by prior treatment experience
In patients who had not previously received treatment, Bayer reported improvements through week 24 in vision and central retinal thickness, an anatomical measure. In previously treated patients, Bayer reported maintained vision alongside improved anatomical measures.
Bayer also reported that treatment intervals were extended for some previously treated patients. This finding concerned only part of that group and should not be read as a uniform dosing outcome for every patient.
Where the findings were presented
Bayer presented the analysis at the EURETINA annual meeting held in Vienna, Austria, from October 1 to 4, 2026.
Frequently asked questions
Did vision improve with Eylea 8 mg in routine care?
Bayer reported vision improvement through week 24 among previously untreated participants with neovascular age-related macular degeneration or diabetic macular edema. Previously treated participants maintained vision while anatomical measures improved. These findings come from a non-interventional 24-week analysis and do not establish comparative efficacy against another regimen.
Were Eylea 8 mg treatment intervals extended?
Bayer reported interval extension in some previously treated patients. The observation applied to only part of that group, so an individual schedule requires assessment by a treating retinal specialist.
Questions to discuss with a retinal specialist
- Does my diagnosis match one of the two retinal conditions included in SPECTRUM?
- How does my previous treatment experience affect the interpretation of these findings?
- Which vision and retinal measurements should be followed during treatment?
MediIndex articles are for general information only and are not medical advice, diagnosis, or advertising. Outcomes vary by individual — consult a board-certified specialist for personal decisions.
